Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization

27. maj 2026 opdateret af: Liu Qiang
  1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery;
  2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery;
  3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients who have undergone coronary revascularization will be randomly assigned to receive either Qidan Xiaohe Granules or a matching placebo, in addition to standard medical therapy. The treatment period lasts 12 weeks, and participants will be followed up for a total of 48 weeks. The main goal is to see whether adding the Chinese herbal medicine reduces the occurrence of major adverse cardiovascular events such as death, heart attack, recurrent chest pain, or repeat revascularization. Secondary goals include improvements in heart function, quality of life, and traditional Chinese medicine symptom scores. Safety will be monitored throughout the study. The results will help determine whether this herbal formula can be recommended as an effective and safe rehabilitation treatment for patients after coronary revascularization.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

164

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Age: 18-80 years old;
  2. no gender limitation;
  3. Meets the diagnostic criteria for coronary heart disease;
  4. Accepts effective PCI procedure;
  5. Voluntarily participates and signs a written informed consent form.

Exclusion Criteria:

  1. Severe hepatic and/or renal insufficiency
  2. Severe electrolyte disorders
  3. Severe hematological diseases or malignant tumors
  4. Pregnant or breastfeeding women
  5. Patients with mental illness
  6. Cognitive impairment (e.g., dementia, post-stroke cognitive impairment) leading to inability to communicate normally
  7. Planning to undergo another revascularization surgery in the near future
  8. Other severe cardiovascular diseases (e.g., uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block without a pacemaker implanted, acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, acute aortic dissection, etc.)
  9. Acute pulmonary embolism and chronic lung diseases with dyspnea symptoms (occurring at rest or with minimal exertion)
  10. Explicit exclusion criteria (bleeding history within 1 month, active bleeding, bleeding tendency, currently using anticoagulants)
  11. Participants in other interventional clinical trials within the past month
  12. Allergy to known components of the investigational drug (Qidan Xiaohe Granules)
  13. Other conditions deemed unsuitable for participation in the trial by the investigator

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental Group
Participants in this arm receive standard medical therapy for coronary heart disease according to current guidelines, including dual antiplatelet therapy , statins, beta-blockers, ACEI/ARB, and other medications as clinically indicated. In addition, they take Qidan Xiaoke Granules orally, one sachet twice daily for 12 consecutive weeks. The granules are dissolved in warm water before administration. The intervention period is 12 weeks, with follow-up assessments at 24, 36, and 48 weeks after baseline. The primary outcome is the incidence of major adverse cardiovascular events (MACE) within 48 weeks.
Medicin: Qidan Xiaoke Granules + Standard Medical Therapy
Participants in this arm receive standard medical therapy for coronary heart disease according to current guidelines, including dual antiplatelet therapy, statins, beta-blockers, ACEI/ARB, and other medications as clinically indicated. In addition, they take Qidan Xiaoke Granules orally, one sachet twice daily for 12 consecutive weeks. The granules are dissolved in warm water before administration. The intervention period is 12 weeks, with follow-up assessments at 24, 36, and 48 weeks after baseline. The primary outcome is the incidence of major adverse cardiovascular events (MACE) within 48 weeks.
Placebo komparator: Control Group
Participants in this arm receive the same standard medical therapy as the experimental group. In addition, they take a placebo matching the Qidan Xiaoke Granules in appearance, taste, odor, and packaging at the same dosage regimen: one sachet twice daily for 12 weeks. The placebo has no pharmacological activity related to the investigational product. The treatment and follow-up schedule are identical to the experimental group.
Medicin: Placebo + Standard Medical Therapy
Participants in this arm receive the same standard medical therapy as the experimental group. In addition, they take a placebo matching the Qidan Xiaoke Granules in appearance, taste, odor, and packaging at the same dosage regimen: one sachet twice daily for 12 weeks. The placebo has no pharmacological activity related to the investigational product. The treatment and follow-up schedule are identical to the experimental group.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence Rate of Major Adverse Cardiovascular Events (MACE)
Tidsramme: Within 48 weeks after randomization
MACE is defined as a composite endpoint including the following seven events: (1) all-cause death; (2) subacute stent thrombosis; (3) peri-procedural myocardial infarction; (4) recurrent myocardial infarction; (5) recurrent unstable angina; (6) repeat revascularization ; and (7) rehospitalization due to angina or heart failure. All events are adjudicated by an independent Clinical Endpoint Committee blinded to treatment allocation, based on source documents.
Within 48 weeks after randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Traditional Chinese Medicine Syndrome Score
Tidsramme: Baseline (day 0), week 6, week 12, week 24, week 36, week 48
The scale evaluates 14 symptoms. Each symptom is scored as 0 (none), 1 (mild), 2 (moderate), or 3 (severe). Tongue appearance (color, coating) and pulse pattern are also recorded. With higher scores indicating more severe TCM syndrome. Assessments are performed by two trained TCM physicians independently; discrepancies are resolved by a third senior physician.
Baseline (day 0), week 6, week 12, week 24, week 36, week 48
Echocardiographic Parameters of Cardiac Structure and Function
Tidsramme: Baseline, week 12
Echocardiography is performed using a standardized protocol at each participating site. Parameters measured include: (1) Left ventricular ejection fraction ; (2) Left ventricular end-diastolic diameter (LVEDD); (3) Left ventricular end-systolic diameter (LVESD); (4) Left ventricular posterior wall thickness (LVPW); (5) Interventricular septal thickness (IVS); (6) E/A ratio (peak velocity of early to late diastolic filling); (7) Average E/e' ratio (mitral inflow to annular velocity). All measurements are performed by certified sonographers following a centralized training program.
Baseline, week 12
24-Hour Holter Monitoring Parameters
Tidsramme: Baseline, week 12
Mean heart rate, PVC count, paired PVCs/ventricular tachycardia, atrial fibrillation, ST-segment depression events, etc.
Baseline, week 12
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Tidsramme: Baseline, week 6, week 12, week 24, week 36, week 48
The MLHFQ is a 21-item, self-administered questionnaire that assesses the impact of heart failure on health-related quality of life. Each item is scored from 0 (no impact) to 5 (very severe impact). With higher scores indicating worse quality of life. The questionnaire is administered in the validated Chinese version.
Baseline, week 6, week 12, week 24, week 36, week 48
Creatine Kinase-Myocardial Band (CK-MB)
Tidsramme: Baseline, week 12
Serum CK-MB measured from fasting blood samples.
Baseline, week 12
Serum Lipid Profile
Tidsramme: Baseline, week 12
Fasting TC, TG, LDL-C, HDL-C measured by enzymatic methods.
Baseline, week 12
Fasting Glucose
Tidsramme: Baseline, week 12
Fasting blood glucose measured using standard laboratory methods.
Baseline, week 12
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
Tidsramme: Baseline, week 12
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
Baseline, week 12

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Red blood cell count
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken for a complete blood count at the time points specified in the study.
Baseline, week 12
Haemoglobin concentration
Tidsramme: Baseline, week 12
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
Baseline, week 12
White blood cell count
Tidsramme: Baseline, week 12
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
Baseline, week 12
Platelet count
Tidsramme: Baseline, week 12
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
Baseline, week 12
Haematocrit
Tidsramme: Baseline, week 12
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
Baseline, week 12
Alanine transaminase
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Aspartate transaminase
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Alkaline phosphatase
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Potassium
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Sodium
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Total bilirubin
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Blood urea nitrogen
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Creatinine
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Uric acid
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12
Homocysteine
Tidsramme: Baseline, week 12
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
Baseline, week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Liu Qiang

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

30. juni 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

14. maj 2026

Først indsendt, der opfyldte QC-kriterier

27. maj 2026

Først opslået (Faktiske)

1. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ZSLL-KY-2026-028-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Data not shared due to patient privacy protection, ethical constraints, and national regulations on human genetic resources.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Koronararteriesygdom

Kliniske forsøg med Qidan Xiaoke Granules + Standard Medical Therapy

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Guatemala

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner